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ardiac Natriuretic Peptides
aining Further Insights Into
tructure–Function Relationships*
dolfo J. de Bold, PHD
ttawa, Ontario, Canada
hile the initial investigations on the physiological and
athophysiological functions of the cardiac natriuretic pep-
ides (NP), atrial natriuretic peptide (ANP), also known as
trial natriuretic factor (ANF), and B-type natriuretic pep-
ide (BNP), centered on their role in the maintenance of
ater and electrolyte balance and other determinants of
xtracellular blood volume and vascular tone, the NP field
as reached unexpected realms, including inflammation,
ipid metabolism, and behavior, all described in many
housands of publications accumulated in the scientific
iterature since the discovery of ANF in 1981 (1). Not less
ignificant is the use of these hormones as therapeutic
gents and as biomarkers of cardiac disease (2–4).
See page 1024
The plethora of biological actions of the cardiac NP
tems from their interaction with the natriuretic peptide
eceptor type A (NPRA) cognate receptor resulting in the
eneration of 3=,5=-cyclic guanosine monophosphate
cGMP). In this manner, receptor-mediated signaling mod-
lates the activity of cGMP-dependent phosphodiesterases,
inases, and ion channels, all of which are present in nearly
ll cell types. These broad targets confer the participation of
Ps in a wide variety of complex biological, physiological,
nd sometimes unexpected processes (5). A very good
xample of that is presented in the article by McKie et al. (6)
n this issue of the Journal. These investigators report the
iological properties of a mutant ANP identified in associ-
tion with a familial form of atrial fibrillation (7). The
utation in the NPPA gene results in a frameshift that
ranslates into the production of an anomalous 40-amino
cid hormone, which is 12 amino acids longer by carboxyl
xtension than the circulating native 28-amino acid ANP.
cKie et al. (6) show that this results in enhanced
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From the Cardiovascular Endocrinology Laboratory, University of Ottawa Heart
nstitute, Ottawa, Ontario, Canada.atriuretic and diuretic effects and in an increased glomer-
lar filtration rate, increased suppression of the renin-
ngiotensin-aldosterone system, and greater cardiac unload-
ng and blood pressure-lowering properties when compared
ith native ANP. Albeit modest, these changes are statis-
ically significant, and importantly, they suggest strategies to
mprove upon the biological potency or the half-life of the
ormone for therapeutic purposes in cardiorenal disease.
his is a reasonable objective because although BNP has
eceived Food and Drug Administration approval for the
reatment of acutely decompensated congestive heart failure,
ative ANP has been shown to be 10-fold more potent
han BNP in promoting cGMP production (8,9) and to
ave 50 times more affinity for the NPRA receptor than
NP (10). In addition, intravenous administration of ANP
nhibits reperfusion injury, prevents LV remodeling, and
mproves LV function in patients with acute myocardial
nfarction (reviewed by Kasama et al. [11]).
Several attempts to exploit expected beneficial actions of
levated NP blood levels in a chronic setting such as
ssential hypertension and chronic congestive heart failure
ave been made. For various reasons, including insufficient
r undesirable effects, attempts to decrease the catabolic rate
f NP, and hence increase their circulating levels through
he use of pharmacological agents that inhibit the NP-
egrading enzyme neutral endopeptidase 24.11 or agents
hat combine this property with angiotensin-converting
nzyme inhibitor activity, have not prospered so far. Mim-
cking compounds that would effectively activate the NPRA
eceptor have not been reported nor have compounds that
ould increase the sensitivity of this receptor to their natural
igands. An alternative approach—the development of re-
ombinant proteins that fuse NP to serum albumin while
reserving NP activity and greatly increasing half-life—may
rove of particular interest (12). Lastly, modifications in the
NP molecule with the purpose of increasing its potency or
iological half-life would likely remain a target of develop-
ent after the findings reported by McKie et al. (6).
Of central importance is that the diverse pharmacological
roperties of ANP amount to a combination of the phar-
acological properties of the different compounds making
p the complex and expensive polypharmacy now used to
reat acute myocardial infarction and congestive heart fail-
re. What is more, ANP exerts these effects while simulta-
eously preventing deleterious rebound phenomena such as
he activation of the renin-angiotensin-aldosterone and
ympathetic nervous systems that occur with current drug
herapies.
In view of the association of mutant ANP with the above
ype of familial atrial fibrillation, it may well be worth
nvestigating its molecular basis by taking into account that
he storage form of ANP in the storage granules present in
trial cardiomyocytes is pro-ANP and that by extension,
ro-ANP must also be a mutant form in these patients. This
oint acquires particular relevance when considering that
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Natriuretic Peptides September 8, 2009:1033–4sing a yeast–2-hybrid approach, we recently demonstrated
hat, within the atrial cardiomyocytes, pro-ANP interacts
ith the calcium-activated potassium channel SK4 (13). It
ay be suggested that mutations in the pro-ANP molecule
ay cause an abnormal association with this or other ion
hannels, thus altering cellular targeting of such channels
nd potentially giving rise to pathologies in excitation or
onduction.
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